GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Price-to-Tangible-Book

Dianthus Therapeutics (Dianthus Therapeutics) Price-to-Tangible-Book : 2.18 (As of May. 16, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Price-to-Tangible-Book?

As of today (2024-05-16), Dianthus Therapeutics's share price is $27.69. Dianthus Therapeutics's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $12.70. Hence, Dianthus Therapeutics's Price to Tangible Book Ratio of today is 2.18.

The historical rank and industry rank for Dianthus Therapeutics's Price-to-Tangible-Book or its related term are showing as below:

DNTH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.91   Med: 1.14   Max: 2.36
Current: 2.18

During the past 3 years, Dianthus Therapeutics's highest Price to Tangible Book Ratio was 2.36. The lowest was 0.91. And the median was 1.14.

DNTH's Price-to-Tangible-Book is ranked better than
61.25% of 1231 companies
in the Biotechnology industry
Industry Median: 2.81 vs DNTH: 2.18

A closely related ratio is called PB Ratio. As of today, Dianthus Therapeutics's share price is $27.69. Dianthus Therapeutics's Book Value per Sharefor the quarter that ended in Mar. 2024 was $12.70. Hence, Dianthus Therapeutics's P/B Ratio of today is 2.18.


Dianthus Therapeutics Price-to-Tangible-Book Historical Data

The historical data trend for Dianthus Therapeutics's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Price-to-Tangible-Book Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - 0.91

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial - - 1.14 0.91 2.36

Competitive Comparison of Dianthus Therapeutics's Price-to-Tangible-Book

For the Biotechnology subindustry, Dianthus Therapeutics's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dianthus Therapeutics's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Dianthus Therapeutics's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Dianthus Therapeutics's Price-to-Tangible-Book falls into.



Dianthus Therapeutics Price-to-Tangible-Book Calculation

Dianthus Therapeutics's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=27.69/12.699
=2.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Dianthus Therapeutics Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines